Adult Vaccinations

In its annual update to the Child and Adolescent Immunization Schedule, federal health officials have made a number of changes, including significant updates to the recommendations for hepatitis A and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis adsorbed (Tdap) vaccination. 1 Andrew Kroger, MD, MPH, Actin Education Team Lead for the Immunization Services Division at the Centers for Disease Control and Prevention (CDC), says these 2 vaccines had the most significant changes in the 2020 update. “Hepatitis A vaccine is now recommended for catch-up vaccination of all children through age 18 years—previously it was through age 2 years,” he says, adding that there are 2 new recommendations concerning the Tdap vaccine. “Previously, a one-time dose of Tdap was recommended for persons aged 7 years and older as protection from pertussis, and for continued tetanus protection follow-up doses could be Td. Now, for the follow-up doses, either Td or Tdap can be admi...

A scientist works in a lab at Moderna in Cambridge, Mass., in February. Moderna has developed an experimental coronavirus medicine, but an approved treatment could be more than a year away. David L. Ryan/Boston Globe via Getty Images hide caption toggle caption David L. Ryan/Boston Globe via Getty Images A scientist works in a lab at Moderna in Cambridge, Mass., in February. Moderna has developed an experimental coronavirus medicine, but an approved treatment could be more than a year away. David L. Ryan/Boston Globe via Getty Images The Department of Health and Human Services outlined how it will support Moderna and Johnson & Johnson as they develop vaccines against the novel coronavirus that's sickened more than 800,000 people worldwide as of Tuesday afternoon. HHS's Biomedical Advanced Research and Development Authority, BARDA, said Monday that it will help speed up clinical trials for both companies' experimental vaccines, and support Janssen Ph...

[unable to retrieve full-text content] Covid-19 vaccine in 18 months? Experts are skeptical.    CNN

As the novel coronavirus continues to spread across the country, those who are not infected can protect themselves by avoiding close contact with others and aggressively washing their hands . But beyond this, many are desperately hoping for another form of protection: a vaccine. Vaccines work by exposing our bodies to something that resembles a certain pathogen, training our immune systems to recognize, attack and kill the invader. When presented with the real pathogen itself, our immune armies are ready to fight. While not a treatment or cure, vaccines can help eradicate a disease by starving the virus of people to infect and transmit the disease. Vaccines are especially needed by health care workers on the front lines and other vulnerable members of the population who have a higher risk of contracting the infection. While the race to develop a COVID-19 vaccine is well underway with over 40 hopeful candidates , only three have entered “Phase I” of clinical trials, the first of t...

The doctor is injecting male patients.In the medical's hand have syringes. Getty Researchers in a handful of countries are testing a century-old tuberculosis vaccine to see if it can give a boost to the immune system to help it fight off the novel coronavirus now causing the COVID-19 pandemic . Clinical trials of the Bacille Calmette-Guerin (BCG) vaccine , which was first developed in the early 1920s, are planned in Europe and Australia to see if it can help reduce the prevalence and severity of COVID-19 symptoms. R esearchers from the Murdoch Children’s Research Institute (MCRI) in Melbourne are currently working to enroll 4,000 healthcare workers from hospitals around Australia in one study. “This trial will allow the vaccine’s effectiveness against COVID-19 symptoms to be properly tested, and may help save the lives of our heroic frontline healthcare workers,” MCRI Director Professor Kathryn North said in a release . A separate large-scale study is planned to include...

IMAGE:  Note: BLM = Black Lives Matter; IRA = Internet Research Agency. Fig. 2a (top) and 2b (bottom): Nodes (circles) represent the various Internet Research Agency accounts. Edges (lines) represent topical... view more  Credit: D. Walter, , "Russian Twitter Accounts and the Partisan Polarization of Vaccine Discourse, 2015-2017, " American Journal of Public Health. Published online ahead of print, March 19, 2020: e1-e7. doi:10.2105/AJPH.2019.305564... During the 2016 election cycle, politically polarizing tweets by Russian trolls about vaccination included pro- and anti-vaccination messages targeted at people with specific political inclinations through an assortment of fake persona types, according to a new analysis published this month. This study encompassed more than 2.8 million tweets published by 2,689 accounts operated by the Russian Internet Research Agency (IRA) from 2015-17. Researchers identified nine types of troll personas, from fake Black Lives Matter...

BLOOMBERG NEWS Pri vate pharmaceutical companies and the National Institutes of Health have outdone themselves. Thanks to the funding provided by the NIH, a Phase 1 clinical trial for a COVID-19 vaccine   is underway . In separate efforts, Inovio, Sanofi, Vaxart, GlaxoSmithKline, and Johnson & Johnson are all developing potential vaccines . In total , “about 35 companies and academic institutions are racing to create a vaccine, at least four of which already have candidates they have been testing in animals. The first of these – produced by Boston-based biotech firm Moderna – will enter human trials imminently.” The speed with which the pharmaceutical industry and public health authorities have worked to develop a vaccine is truly remarkable. The dynamic response demonstrates how a vibrant pharmaceutical industry working in tandem with a focused public health authority can meet 21 st Century pandemic threats. Once developed and approved, it is imperative that patients...

Disclaimer: This post is from GomerBlog , a satirical site about healthcare. CDC officials announced Tuesday that they believe the new vaccine currently under development aimed at controlling the rapidly spreading SARS-CoV-2 virus -- responsible for causing COVID-19 -- will be approved and ready to be utterly rejected by those in the anti-vaccination (anti-vax) movement by next year. "This is an exciting development," said Eric Polsky, director of the CDC's Novel Vaccination Program, "and we will work tirelessly to ensure all anti-vaxxers have the opportunity to decline, refuse, and reject this potentially life-saving vaccine as early as possible." The announcement has many in the anti-vaccination movement excited, including a local woman present at the press conference, who noted, "I just get such a thrill from ignoring mountains of scientific evidence at the danger of threatening the world around me, and the chance to do that by yet again opting out ...

The coronavirus outbreak could lead to a resurgence of childhood diseases such as measles and polio, as the pandemic has shut down routine vaccination schedules and disrupted supply chains, experts have warned. While the unprecedented interventions introduced to stem the Covid-19 pandemic should prevent other disease outbreaks in the short term there is a real concern about a potential explosion of infectious, preventable illnesses when life returns to “normal”.  Across the globe, planned efforts to vaccinate children against childhood diseases, including measles and polio, have already been suspended.  Dr Robin Nandy, global chief of immunisation at Unicef, told the Telegraph that the UN agency has paused all routine and emergency vaccinations because of concerns that they could further the spread of the coronavirus .  “We do not want to contribute to the Covid problem through immunisation programmes, so we are recommending that all campaigns are tem...

As the coronavirus pandemic spreads across the United States and our world, I worry about friends, family, and my community in general. The virus has the potential to be truly devastating, with the potential to cause thousands of deaths, especially among the elderly. Fortunately there is a ray of good news: the virus does not seem to cause severe disease in children. In fact, the data from China which has experienced a majority of the cases and deaths, has been reassuring. Of approximately 3,300 deaths to date, no child. While the elderly are at risk for developing severe and life-threatening infections, children and young adults are more likely to have mild symptoms such as nasal congestion, sore throat and a mild cough. The good news is that our children seem to be spared, but there is a down side as well: since children have mild symptoms, they have the potential to easily spread the coronavirus to adults. Not only should adults stay home when ill, but it is also vital that ch...

Though the 2020 in-person meeting of the Society of Gynecologic Oncology was put on hold due to the ongoing COVID-19 pandemic, the meeting's scientific abstracts have now been released, and a selected few are summarized below. Adjuvant HPV Vaccine Reduces Repeat Cervical Precancer s Women undergoing surgery for high-grade cervical intraepithelial neoplasia (CIN)2/3 had significantly lower risk for recurrence if they subsequently received a human papillomavirus (HPV) vaccination, a meta-analysis and systematic review found. Among nearly 3,000 women undergoing surgical excision, recurrence of high-grade dysplasia (CIN2/3) occurred in 1.7% of women who received vaccination, as compared with 4.7% of those that received placebo or surgery alone (relative risk 0.34, 95% CI 0.22-0.55), reported Kim Levinson, MD, of Johns Hopkins University School of Medicine in Baltimore. Risk of any-grade CIN was also significantly lower with vaccination than without (6.3% vs 9.7%, respectively, RR ...

In its annual update to the Child and Adolescent Immunization Schedule, federal health officials have made a number of changes, including significant updates to the recommendations for hepatitis A and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis adsorbed (Tdap) vaccination. 1 Andrew Kroger, MD, MPH, Actin Education Team Lead for the Immunization Services Division at the Centers for Disease Control and Prevention (CDC), says these 2 vaccines had the most significant changes in the 2020 update. “Hepatitis A vaccine is now recommended for catch-up vaccination of all children through age 18 years—previously it was through age 2 years,” he says, adding that there are 2 new recommendations concerning the Tdap vaccine. “Previously, a one-time dose of Tdap was recommended for persons aged 7 years and older as protection from pertussis, and for continued tetanus protection follow-up doses could be Td. Now, for the follow-up doses, either Td or Tdap can be admi...

[unable to retrieve full-text content] UAB to test a possible COVID-19 vaccine    Alabama's News Leader

When the late Bob Simon interviewed Gary Kobinger for 60 Minutes in 2015, Kobinger was working principally in a space suit in a special clean room behind bulletproof glass. At the time, he was a top virologist at Canada’s National Microbiology Lab, where he became a critical player in the development of the early Ebola vaccine ZMapp. Now he’s the director of the Infectious Disease Research Center at the Université Laval in Quebec City, his hometown. His lab helped with the early development of Inovio Pharmaceuticals’ Zika vaccine in 2017. Today, Kobinger is among hundreds of scientists worldwide working on potential Covid-19 vaccines; he is working with Inovio and Medicago, another drug company. WIRED talked with Kobinger by phone last week. The conversation has been condensed and edited. WIRED: You've been watching and helping with epidemics your entire career. How does Covid-19 compare to, say, the Ebola epidemic? GARY KOBINGER: Well, it's on a global scale of cours...

The report involves insightful data on the main sectors of the Global Hepatitis A Vaccine, Inactivated Market . The report has segmented market, by its types and applications. Each segment has analyzed completely on the basis of its production, consumption as well as revenue. Further, it is classified on the basis of geographical areas which include: North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The study on the Hepatitis A Vaccine, Inactivated market provides complete report on changing market trends for this market. It offers market size and share of each separate segment in the market. Many companies are involved in this market. Top players are completely profiled in this report. Our best analysts have surveyed the market report with the reference of inventories and data given by the key players: GlaxoSmithKline Merck Sanofi Berna Biotech Norvatis Sinovac Checkout Free Report Sample of Hepatitis A Vaccine, Inactivated Market Report for Better ...

March 31 (Reuters) - ExpreS2ion Biotech Holding AB : * EXPRES2ION ANNOUNCES 6.7 MSEK EU HORIZON 2020 GRANT FOR THE DEVELOPMENT OF A UNIQUE INFLUENZA VACCINE * GRANT, IS ESTIMATED TO BE RECOGNISED AS REVENUE EVENLY FROM H2 2020 THROUGH H2 2021 Source text for Eikon: Further company coverage: (Gdansk Newsroom) Our Standards: The Thomson Reuters Trust Principles.

A century-old tuberculosis vaccine could protect health care workers from the coronavirus, according to a report. Some 4,000 health workers in hospitals across Australia will be administered the bacillus Calmette-Guerin, or BCG vaccine, as part of a six-month trial set to begin Monday, Bloomberg reported . Researchers at the Murdoch Children’s Research Institute in Melbourne will be probing whether the vaccine — which has been widely used for about 100 years — can reduce COVID-19 symptoms. “Although originally developed against tuberculosis, and still given to over 130 million babies annually for that purpose, BCG also boosts humans’ ‘frontline’ immunity, training it to respond to germs with greater intensity,” researchers said in a statement. The participants will be enrolled in the trial within weeks following fast-track approval from health authorities. “The clock is definitely ticking,” said lead researcher Nigel Curtis, a professor of pediatric infectious diseases at the Univ...

Editor’s note: With our coronavirus coverage, our goal is not to alarm you but to equip you with the information you need. We will try to keep things in context and focus on helping you make decisions. See a list of resources and frequently asked questions here. As worldwide cases approach 700,000 and virus-related deaths top 33,000 as of Monday , 35 companies and academic institutions are racing to create a vaccine against coronavirus/COVID-19. The latest among them is Johnson & Johnson , the world’s largest healthcare company, which says the vaccine would be ready for clinical human trials in September. Vaccines would be ready for emergency use by early 2021, the company says. Most health officials say that even on an accelerated timeline, the fall of 2021 is the earliest that a COVID-19 vaccine would be widely available. Johnson & Johnson's initial COVID-19 vaccine development began in January, and the company has since committed more than $1 billion to the vaccine...

Vaccine vial dose with needle syringe, medical concept vaccination in laboratory background Getty What should the public know about vaccine development as a whole?  originally appeared on  Quora : the place to gain and share knowledge, empowering people to learn from others and better understand the world.   Answer  by  Gene Olinger, PhD , Science Advisor with MRIGlobal, professor at Boston University’s School of Medicine, Dept. of Medicine, and Division of Infectious Diseases, in their  Session :   Vaccine development is a laborious and costly endeavor. Typically, a vaccine takes 10 years and $1 billion USD to be used in the general population. Benefit versus Risk is the key to vaccine development. The vaccine must offer a benefit that outweighs the risks. Fortunately, the work of the past 100 years, more so the past three decades, has helped to decrease the time needed to develop a candidate and test it in clinical trials. We are close t...